| Price Range 12mo avg: | $2M – $2.5M |
|---|---|
| $/sf 12mo avg: | $318.75 |
| CAP Rate 12mo avg: | 7.29% |
| NOI average: | $173,700 |
| Lease Terms: | 15yrs NNN |
| Building Size avg: | 7,500 SF |
| Lot Size avg: | 2.5+/- acres |
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
| S&P Credit Rating: | BBB- |
|---|---|
| Moody’s Credit Rating: | Ba1 |
| Annual Revenue 2014: | $15.8B |
| Annual Revenue 2013: | $14.6B |
| Revenue Growth: | ↑ 8% from 2013 |
| Net Income | $1.05B |
| Units (Dec. 2014) | 3,361 |
| Average Units Volume: | $4.7M |
Yahoo! Finance: FMS News Latest Financial News for FMS
-
U.S. Renal Care, Inc (New) -- Moody's assigns a Caa2 rating to the senior unsecured notes of US Renal Care, Inc. (NEW)
on June 7, 2019 at 9:11 pm
Moody's Investors Service ("Moody's") today assigned a Caa2 rating to U.S. Renal Care, Inc.'s (NEW) ("U.S. Renal") new senior unsecured notes. There is no change to the company's existing ratings, including the B3 Corporate Family Rating, B3-PD Probability of Default Rating, and B2 ratings on the company's new senior secured revolving credit facility and term loan. Moody's expects that the proceeds from these notes, along with the company's proposed credit facility and equity, will be used to finance the $2.7 billion leveraged buyout of the company by a consortium of private equity investors led by Bain Capital and Summit Partners. […]
-
INSIGHT-Will Europe's clampdown on faulty medical devices hurt patients?
on June 6, 2019 at 6:00 am
When a Californian company founded by a U.S. veteran wounded in Afghanistan sought to register a new medical device this year, it turned to Europe before the United States. "Now it has flipped," said Bill Colone, CEO of San Clemente-based Spinal Singularity, which hopes to launch a 'smart' catheter for men with spinal injuries or disease early next year after squeezing in its application under the old European rules. Colone is part of a chorus of industry voices warning that a switch to stricter European rules governing medical devices, due to come into force a year from now, will slow or even halt the release of products in Europe that could transform patients' lives. […]
-
Is Cara Therapeutics a Buy Now?
on June 2, 2019 at 1:09 pm
A pivotal trial for the company's lead candidate was an unequivocal success. […]
-
U.S. RENAL CARE, INC. (NEW) -- Moody's assigns a B3 CFR to US Renal Care, Inc. (NEW); outlook stable
on May 30, 2019 at 4:28 pm
The rating agency also assigned a B2 rating to the company's new senior secured revolving credit facility and term loan. Moody's expects that the proceeds from the proposed credit facility, along with the issuance of junior debt capital and equity, will be used to finance the $2.7 billion leveraged buyout of the company by a consortium of private equity investors led by Bain Capital and Summit Partners. […]
-
Cara Shares Up on Positive Phase III Data for Itchiness Drug
on May 30, 2019 at 11:48 am
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus. […]
NYSE: FMS
